CE Education

Acute myeloid leukemia (AML) is the second most common blood cancer in children. In current care, clinicians are working to identify specific molecular subtypes in AML. In this activity, Dr. Aplenc explains how we might tailor therapies to these subtypes and how new therapies may improve outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Jazz Pharmaceuticals.

Acute myeloid leukemia is a disease of older individuals, with the median age of presentation being between 67 to 70 years of age. In this activity, Dr. Wang explains prognostic factors, including mutational profiling, and how they help determine if your patient is ‘fit’ or ‘unfit’ for intensive chemotherapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.

Join Dr. Kolb as he reviews secondary AML treatment options for pediatric patients. Topics include molecular aberrations in childhood AML, limitations of current treatment options (including treatment-related toxicity), and novel agents that may improve outcomes in pediatric patients with secondary AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Jazz Pharmaceuticals.

Join Dr. Jonas as he discusses novel uses for hypomethylating agents (HMAs) in AML and MDS. Topics include venetoclax-based regimens, novel HMA combinations, and HMAs as maintenance therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.

Explore strategies for providing mutation-targeted therapy in acute myeloid leukemia (AML). In this activity, Dr. Fathi will discuss approved and emerging treatments that have shown efficacy for established AML mutations, including IDH1/2, FLT3, and TP53.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.

In this activity, Dr. James M. Foran discusses new concepts in bridging therapy and stem cell transplant in older AML patients. He reviews the safety and efficacy data regarding stem cell transplant in this patient population and explores a number of agents and therapeutic strategies that have been evaluated for bridging to transplant in older AML patients, including midostaurin, CPX-351, decitabine, venetoclax-based regimens, gilteritinib, and the investigational agent Iomab-B.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.

Join Dr. Short as he explores challenges in managing relapsed/refractory AML. Topics include analysis of the role of cytogenetic and molecular aberrations in prognosis and relapse risk, standard and targeted therapies, and new data on emerging therapies for relapsed/refractory AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.

The inclusion of new therapies has augmented the treatment paradigm for AML and has sparked a trend toward outpatient therapy, which necessitates the collaboration of a multidisciplinary team, detailed patient assessment, careful preparation of therapy, and thorough patient monitoring. In this way, successful outpatient administration of treatment for AML may be possible. Recently, MediCom convened a panel of expert faculty in AML to share their experiences and provide practical considerations and guidance for the implementation of an outpatient center for AML therapy. In this activity, three expert faculty present key findings of this consensus, including identification of patients who may be appropriate for outpatient therapy, optimal administration of therapy, and effective implementation of supportive care measures.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Jazz Pharmaceuticals.

Join Dr. Eytan Stein as he explores the evolving treatment landscape for acute myeloid leukemia (AML). Topics to be discussed include new uses of hypomethylating agents and venetoclax, targeted therapies for specific mutations, and investigational low-intensity treatment combinations. Dr. Stein will also extrapolate on expanding concepts such as patient ‘fitness,’ measurable residual disease, and maintenance therapy for AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.

In this activity, Dr. Desai will explore new approaches to maintenance therapy in AML. Topics include a discussion of the study design and results of the QUAZAR AML-001 trial of oral azacitidine for maintenance therapy, findings from the RATIFY study that led to the approval of midostaurin for FLT3-mutated AML, sorafenib for post-allogeneic stem cell transplant maintenance, and decitabine plus recombinant human granulocyte colony-stimulating factor in the post-transplant setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.

Determining fitness for intensive therapy can be challenging to assess in patients with AML. In this activity, Dr. Kendra Sweet describes best practice in assessing fitness for intensive therapy for patients with newly diagnosed AML, the impact of comorbidities, and the available tools that should be utilized to determine a patient's fitness for intensive therapy. She will describe appropriate intensive and non-intensive treatment options for patients with AML based on their fitness.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, Helsinn, and Jazz Pharmaceuticals.

In this activity, experts will review select abstracts from the 2020 ASH Annual Meeting and explore how this data can be used to guide treatment selection in AML. Topics will include outcomes of trials combining venetoclax and hypomethylating agents in both the upfront and second-line setting, new data on FLT3 inhibitor/venetoclax combination therapy, triple therapy with hypomethylating agents, venetoclax, and IDH inhibitors, results from the QUAZAR trial evaluating oral azacitidine versus placebo as maintenance therapy, and new data on CPX-351.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Helsinn Healthcare SA, and Jazz Pharmaceuticals.